ReviewMolecular biology reports2026
Unlocking the potential of cyclic peptides in bioactive wound dressings for enhanced tissue repair.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic peptides have emerged as particularly potent therapeutic agents due to their distinct structural and functional features. It exhibits remarkable versatility through diverse mechanisms of action, including broad-spectrum antimicrobial activity against multidrug-resistant pathogens, precise immunomodulatory functions that facilitate the transition from inflammatory to proliferative phases, enhanced cellular migration and proliferation through growth factor, angiogenesis promotion via VEGF and integrin pathway activation, and sophisticated extracellular matrix modulation. The combination of cyclic peptides and hydrogel technology is one of possible method for treating chronic wounds, such as diabetic foot ulcers. It has been shown to be highly successful in treating extracellular matrix defects, poor angiogenesis, and chronic inflammation in clinical settings. This thorough review literature include the the current status and future possibilities of cyclic peptide-based wound dressings by emphasizing the scalable manufacturing standardization, complete long-term safety profiles, regulatory pathway optimization, and cost-effective manufacturing processes. Future views include AI-driven peptide design, personalized medicine techniques based on wound-specific biomarkers, smart material integration for temporal control, and combination treatments that target various healing pathways at the same time. The combination of computational design, modern manufacturing, and clinical validation positions cyclic peptide-based wound dressings as transformational medicines with the potential to address significant unmet needs in wound treatment.
Indexed as
Identifiers
42489945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.